ELISA

Microbial Transglutaminase (MTG) ELISA


ELISA for the detection of Microbial Transglutaminase (MTG)

Order
Quantity
Price
Status
1 Kit 365 € available


Documents
Art. No. E021
Background info Microbial transglutaminase catalyzes acyl transfer reactions between the γ-carboxyamide group of a protein-bound glutamine residue and primary amines. In simple terms, microbial transglutaminase acts as a biological glue that covalently links proteins. Among others microbial transglutaminase is used in the food industry for the production of dairy products, meat, sausages and bakery products.

The Microbial Transglutaminase (MTG) ELISA (Product Nr. E021) is a sandwich enzyme immunoassay developed for the quantitative determination of native MTG. As part of the kit development, the following foods were examined: glued meat (raw), yoghurt, quark, cheese, salami and bread. It can be assumed that the test is also suitable for the analysis of further foods. Detection and determination limits depend on the respective sample matrix, the degree of processing and the extraction process.

Please note that for each type of sample material, the preparation procedure must be validated separately by the user.

All reagents for the implementation of the enzyme immunoassay are contained in the test kit. A test kit is sufficient for 96 determinations (including standards). A microtiter plate photometer is required for evaluation.

Sample preparation: homogenizing, extracting
Standard material: Microbial Transglutaminase (0 - 150 ng/mL)
Detection limit: 0.6 ng/mL (ppb) MTG (1 mL ≙ 1 g)
Determination limit: 3.0 ng/mL (ppb) MTG (1 mL ≙ 1 g)

MTG ELISA
Assay principle The microtiter plate wells (solid phase) are coated with antibodies specific to microbial transglutaminase.
1st reaction: Microbial transglutaminase present in the sample binds to the immobilised antibodies, forming the antibody-antigen-complex.
2nd reaction: A microbial transglutaminase specific antibody labeled with biotin binds to the antibody-antigen-complex forming an antibody-antigen-[antibody-biotin] sandwich.
3rd reaction: Streptavidin conjugated to horseradish peroxidase (HRP) binds to the biotin-label fo the antibody-antigen-[antibody-biotin] sandwich.
4th reaction: The HRP-labeled complex converts a substrate (TMB) into a blue product which upon addition of the stop solution turns yellow. Samples containing microbial transglutaminase develop the blue colour (which upon addition of the stop solution turns yellow), whereas samples without microbial transglutaminase remain colourless.
Reagents in the kit Microtiter plate packed in a resealable foil laminate pouch with a dessicant bag
Sample buffer
Wash buffer
MTG-standard.
Purified anti-microbial transglutaminase antibody labeled with biotin (MTG-Ab conjugate)
Streptavidin-HRP conjugate
Substrate solution
Stop solution (0.2 M H2SO4)
Directions for use
Storage Store the whole kit at 6 - 8°C. It is important that the MTG-standard is not stored below 6°C. The kit is stable up to the expiry date stated on the label of the box. Do not use kit beyond its expiry date. After opening the pouch keep unused microtiter wells resealed to minimize exposure to moisture. Substrate solution is sensitive to light, therefore avoid direct exposure to light. After the expiry date (see kit label) no quality guarantee is given.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA